Aug 10, 2026 4:30pm EDT SCYNEXIS Reports Second Quarter 2026 Financial Results and Provides Corporate Update
Jun 30, 2026 8:00am EDT SCYNEXIS Initiates Phase 1 Study of SCY-770, a Novel AMPK Activator for the Treatment of Autosomal Dominant Polycystic Kidney Disease (ADPKD)